Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial")
MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge med
(Financial Post, 2025-10-15T13:20:40Z)